Literature DB >> 17639169

Childhood macrophage activation syndrome differs from infection-associated hemophagocytosis syndrome in etiology and outcome in Taiwan.

Hsin Hsu Chen1, Ho Chang Kuo, Ling Wang, Hong Ren Yu, Jiun Min Shen, Kao Pin Kwang, Kuender D Yang.   

Abstract

BACKGROUND AND
PURPOSE: Hemophagocytic lymphohistiocytosis (HLH) is a syndrome composed of macrophage activation syndrome (MAS), infection-associated hemophagocytosis syndrome (IAHS), malignancy-associated HLH and genetic HLH. Differentiation of MAS from IAHS and other HLH is important for early appropriate treatment.
METHODS: A retrospective analysis was used to differentiate childhood MAS from IAHS and other HLH in Chang Gung Memorial Hospital (CGMH), Kaohsiung. All relevant clinical features, laboratory data, treatments and outcomes were analysed.
RESULTS: Seventeen patients with childhood HLH were found at CGMH, Kaohsiung in the past decade, and could be classified into 3 categories: IAHS (9 patients), MAS (5 patients), and HLH of unknown etiology (3 patients). The diagnosis of MAS first appeared in this hospital in 2001. Patients with IAHS tended to be younger than those with MAS. Boys were more frequently found in the IAHS group whereas girls (with systemic lupus erythematosus or juvenile idiopathic arthritis) were more frequently found in the MAS group. The majority of mortality cases were noted in the IAHS group (44%, 4/9). All patients with MAS survived with early cyclosporine A treatment.
CONCLUSIONS: Childhood MAS is different from IAHS in terms of age, gender, etiology and mortality. Early administration of cyclosporine A for MAS results in a lower mortality. Further prospective studies are required to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17639169

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  3 in total

1.  Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India.

Authors:  Surjit Singh; Shanmuganathan Chandrakasan; Jasmina Ahluwalia; Deepti Suri; Amit Rawat; Nishath Ahmed; Reena Das; M U S Sachdeva; Neelam Varma
Journal:  Rheumatol Int       Date:  2011-01-11       Impact factor: 3.580

2.  Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases.

Authors:  Cheng-I Lin; Hsin-Hui Yu; Jyh-Hong Lee; Li-Chieh Wang; Yu-Tsan Lin; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Clin Rheumatol       Date:  2012-05-22       Impact factor: 3.650

3.  Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis.

Authors:  Pilar Brito-Zerón; Belchin Kostov; Pedro Moral-Moral; Aleida Martínez-Zapico; Carmen Díaz-Pedroche; Guadalupe Fraile; Patricia Pérez-Guerrero; Eva Fonseca; Angel Robles; María P Vaquero-Herrero; María Andrés Calvo; María José Forner; Cesar Morcillo; José Larrañaga; Monica Rodriguez-Carballeira; Manuel Ruiz-Muñoz; Robert Hurtado-García; Sergio Prieto-González; Asun Aljibe Aguilar; Luis Caminal-Montero; Pilar Hernández-Jiménez; Cristina Rodríguez Fernández-Viagas; Pedro Castro; Victoria Morell Massó; Alejandra Flores-Chavez; Manuel Ramos-Casals
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2018-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.